Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Ambit Biosciences begins dosing in leukemia trial
The phase I trial is a dose-escalation study that will enroll patients with relapsed or refractory acute myeloid leukemia (AML). AC220 will be administered daily via oral solution,
The phase I trial is a dose-escalation study that will enroll patients with relapsed or refractory acute myeloid leukemia (AML). AC220 will be administered daily via oral solution,
The first litigation suit concerned the Iridex proprietary laser probe connector technology. The second suit involved the Synergetics directional laser probe technology and the Iridex patent pending application
EpiCept is testing its NP-1 drug for use in two different indications and believes it has the largest market potential of any of its pain product candidates. EpiCept
As part of the merger agreement Inhibitex will gain two antiviral development programs to enhance its anti-infective drug development capabilities, including FV-100, for the treatment of shingles and
GSK and Adolor have suspended two studies investigating Entereg, until further analysis of the data has been completed. The FDA had requested an additional safety study for Entereg
Patients who undergo hepatitis B-related liver transplantation require long-term post-transplant therapy with hepatitis B immune globulin. Clinical trial data showed HepaGam B was highly effective at preventing hepatitis
The proposal was delivered to medical diagnostics company Biosite on April 4th. Biosite has already agreed to a merger buyout with Beckman Coulter, a California company that designs,
Soft tissue sarcoma includes cancers of cartilage, fat, muscle, blood vessels, or other connective or supportive tissue. “The treatment of advanced, soft tissue sarcoma remains a major unmet
Tibotec said it selected Aspen because of its extensive African distribution network. Aspen and Tibotec will share the responsibility for ensuring prompt and affordable access to patients in
Wyeth received an FDA warning letter in May 2006 that raised several specific concerns about manufacturing at the facility. Based on the nature of the inspection observations issued